Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Münster AML-study group
-
- Eva A. Coenen
- Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children’s Hospital, Rotterdam, The Netherlands;
-
- C. Michel Zwaan
- Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children’s Hospital, Rotterdam, The Netherlands;
-
- Dirk Reinhardt
- Acute Myeloid Leukemia-Berlin-Frankfurt-Münster Study Group, Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany;
-
- Christine J. Harrison
- Northern Institute of Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;
-
- Oskar A. Haas
- St. Anna Children's Hospital and Children’s Cancer Research Institute, Department of Pediatrics, Medical University of Vienna, Vienna, Austria;
-
- Valerie de Haas
- Dutch Childhood Oncology Group, the Hague, The Netherlands;
-
- Vladimir Mihál
- Czech Pediatric Hematology/Oncology, Department of Pediatrics, University Hospital, Palacky´s University, Olomouc, Czech Republic;
-
- Barbara De Moerloose
- Belgian Society of Paediatric Haematology Oncology, Ghent University Hospital, Department of Pediatric Hematology/Oncology, Ghent, Belgium;
-
- Marta Jeison
- Cancer Cytogenetic Laboratory, Pediatric Hematology Oncology Department, Schneider Children's Medical Center of Israel, Petach Tikvah, Israel;
-
- Jeffrey E. Rubnitz
- St. Jude Children’s Research Hospital, Memphis, TN;
-
- Daisuke Tomizawa
- Japanese Pediatric Leukemia/Lymphoma Study Group, Department of Pediatrics, Tokyo Medical and Dental University, Tokyo, Japan;
-
- Donna Johnston
- Children’s Oncology Group, Arcadia, CA;
-
- Todd A. Alonzo
- Children’s Oncology Group, Arcadia, CA;
-
- Henrik Hasle
- Nordic Society for Pediatric Hematology and Oncology, Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark;
-
- Anne Auvrignon
- French Leucémie Aique Myeloide Enfant, Hopital Trousseau, Paris, France;
-
- Michael Dworzak
- St. Anna Children's Hospital and Children’s Cancer Research Institute, Department of Pediatrics, Medical University of Vienna, Vienna, Austria;
-
- Andrea Pession
- Italian Association of Pediatric Hematology Oncology, Clinica Pediatrica, Università Padova, Padova, Italy;
-
- Vincent H. J. van der Velden
- Department of Immunology, Erasmus MC, Rotterdam, The Netherlands;
-
- John Swansbury
- Department of Clinical Cytogenetics, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom;
-
- Kit-fai Wong
- Department of Pathology, Queen Elizabeth Hospital, Hong Kong, China;
-
- Kiminori Terui
- Department of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan;
-
- Sureyya Savasan
- Division of Hematology/Oncology, Children’s Hospital of Michigan, Detroit, MI;
-
- Mark Winstanley
- Department of Pediatric Oncology, Starship Children’s Hospital, Auckland, New Zealand; and
-
- Goda Vaitkeviciene
- Clinic for Children’s Diseases, Centre for Oncology/Haematology, Vilnius University, Vilnius, Lithuania
-
- Martin Zimmermann
- Acute Myeloid Leukemia-Berlin-Frankfurt-Münster Study Group, Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany;
-
- Rob Pieters
- Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children’s Hospital, Rotterdam, The Netherlands;
-
- Marry M. van den Heuvel-Eibrink
- Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children’s Hospital, Rotterdam, The Netherlands;
抄録
<jats:title>Key Points</jats:title><jats:p>Pediatric t(8;16)(p11;p13) AML is a rare entity defined by a unique gene expression signature and distinct clinical features. Spontaneous remissions occur in a subset of neonatal t(8;16)(p11;p13) AML cases.</jats:p>
収録刊行物
-
- Blood
-
Blood 122 (15), 2704-2713, 2013-10-10
American Society of Hematology
